|
|
 | | | |
- close
- close
- close
- close
Map Pharmaceuticals Inc (MAPP) |
Benzinga
Mar 1
Comment
In a report published Friday, Wedbush downgraded its rating on MAP Pharmaceuticals (NASDAQ: MAPP) from Outperform to Neutral, and reiterated its $25.00 price target.
Wedbush noted, “Allergan previously announced its intent to acquire Map...
Benzinga
Jan 24
Comment
Canaccord Genuity downgraded MAP Pharmaceuticals (NASDAQ: MAPP) from Buy to Hold and raised the price target from $23.00 to $25.00.
Canaccord Genuity commented, "Post yesterday's announcement of Allergan's (AGN) intention to acquire Map...
StreetInsider.com
Jan 23
Comment
MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) 59% HIGHER; Allergan, Inc. (NYSE: AGN) agreed to acquire MAP Pharmaceuticals, Inc. for $25 per share, or approximately $958 million. The offer represents a 60% premium over MAPs closing stock price on the...
Benzinga
Nov 23
Comment
In a report published Friday, Wedbush Securities reiterated its Outperform rating on MAP Pharmaceuticals (NASDAQ: MAPP).
Wedbush Securities noted, “Map is developing Levadex as a rapid-acting treatment for acute migraine. The company...
StreetInsider.com
Nov 23
Comment
KIT digital, Inc. (NASDAQ: KITD) 54% LOWER; to restates FY09-FY12 results; CEO offers to buy the company.
Research In Motion Limited (NASDAQ: RIMM) 14% HIGHER; rose 18% in Toronto trading on Thursday with U.S. markets closed after positive...
StreetInsider.com
Oct 16
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/MAP+Pharma+%28MAPP%29+Resubmits+LEVADEX+NDA+to+FDA+as+Migraine+Treatment/7794524.html for the full story.
StreetInsider.com
Aug 1
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/MAP+Pharma+%28MAPP%29+Prices+3.88M+Offering+at+%2413.40Share/7621027.html for the full story.
Benzinga
Jul 31
Comment
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. MAP Pharmaceuticals expects to grant the underwriters a 30-day option to purchase an...
StreetInsider.com
Jun 25
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/MAP+Pharma+%28MAPP%29+Says+No+New+Studies+Needed+Following+CRL+Meeting+w+FDA+Over+LEVADEX/7537554.html for the full story.
Benzinga
May 7
Comment
In a company update published earlier today, Ladenburg Thalmann Financial Services reiterated its Buy rating and $24.00 price target for MAP Pharmaceuticals, Inc. (NASDAQ: MAPP).
Ladenburg Thalmann said in its report “We remain positively...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS|
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_2/mediawiki/images/thumb/9/98/New_stock.png/35px-New_stock.png' @ convert.c/ConvertImageCommand/2800. |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
